CD30: An important new target in hematologic malignancies

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1641-1654

  Deutsch, Yehuda E ^a   Tadmor, Tamar ^b   Podack, Eckhard R ^a   Rosenblatt, Joseph D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

antibody based immunotherapy; brentuximab vedotin; CD30; Lymphoma and Hodgkin disease

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CD30 ANTIBODY; CD30 ANTIGEN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRATUMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD30; NAVELBINE; SGN 30; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BLOOD TOXICITY; CYTOTOXICITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; GERM CELL TUMOR; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LUNG TOXICITY; LYMPHOMATOID PAPULOMATOSIS; MULTICENTER STUDY (TOPIC); MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REED STERNBERG CELL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 80052076003     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.574761     Document Type: Review

References (118)

1. Kuruvilla J. Standard therapy of advanced Hodgkin lympho-ma. Hematology Am Soc Hematol Educ Program 2009: 497-506.
2. von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997;151:1123-1130. (Pubitemid 27424322)
3. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327: 1478-1484.
4. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-1418. (Pubitemid 34754624)
5. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395. (Pubitemid 36682817)
6. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-4554.
7. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 2008;19:1795-1801.
8. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555-7564. (Pubitemid 46291819)
9. Brillant C, Bauer K, Herbst C, Monsef I, Skoetz N, Engert A. Escalated BEACOPP versus ABVD-like chemotherapy for Hodgkin lymphoma patients: a Cochrane Review. Blood 2009;114(Suppl. 1):Abstract 3705.
10. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-811.
11. Gianni AM, Rambaldi A, Zinzani PL. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma: a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. J Clin Oncol 2008; 26(Suppl.): Abstract 8506.
12. Byrne BJ, Gockerman JP. Salvage therapy in Hodgkin's lymphoma. Oncologist 2007;12:156-167.
13. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10:210-218.
14. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-1054. (Pubitemid 23114397)
15. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-2071. (Pubitemid 34680969)
16. Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000;85:926-929.
17. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lym-phoma 2004;5:110-115. (Pubitemid 39378321)
18. Aurer I, Radman I, Nemet D, et al. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie 2005;28:567-571. (Pubitemid 41513142)
19. Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998;16:584-588. (Pubitemid 28135603)
20. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994;5:817-820. (Pubitemid 24341874)
21. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-3695.
22. Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park) 2010;24:574-587.
23. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93: 2697-2706. (Pubitemid 29181203)
24. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93: 3913-3921. (Pubitemid 29249840)
25. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:65-67. (Pubitemid 12049770)
26. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-858. (Pubitemid 15242469)
27. Romagnani P, Annunziato F, Manetti R, et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 1998;91:3323-3332. (Pubitemid 28193883)
28. Podack ER, Strbo N, Sotosec V, Muta H. CD30-governor of memory T cells? Ann NY Acad Sci 2002;975:101-113.
29. Sabbagh L, Snell LM, Watts TH. TNF family ligands define niches for T cell memory. Trends Immunol 2007;28:333-339. (Pubitemid 47077923)
30. Nishimura H, Yajima T, Muta H, Podack ER, Tani K, Yoshikai Y. A novel role of CD30/CD30 ligand signaling in the generation of long-lived memory CD8+ T cells. J Immunol 2005;175:4627-4634. (Pubitemid 41362002)
31. Withers DR, Jaensson E, Gaspal F, et al. The survival of memory CD4+ T cells within the gut lamina propria requires OX40 and CD30 signals. J Immunol 2009;183:5079-5084.
32. Gaspal FM, Kim MY, McConnell FM, Raykundalia C, Bekiaris V, Lane PJ. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol 2005;174:3891-3896. (Pubitemid 40395961)
33. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994;83:2045-2056. (Pubitemid 24112714)
34. Shanebeck KD, Maliszewski CR, Kennedy MK, et al. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol 1995;25:2147-2153.
35. Sun X, Somada S, Shibata K, et al. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology 2008;134:447-458.
36. Nam SY, Kim YH, Do JS, et al. CD30 supports lung inflammation. Int Immunol 2008;20:177-184.
37. Tang C, Yamada H, Shibata K, et al. A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J Immunol 2008;181:6316-6327.
38. Annunziato F, Manetti R, Cosmi L, et al. Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells. Eur J Immunol 1997;27:2239-2244. (Pubitemid 27404306)
39. Nakamura T, Lee RK, Nam SY, et al. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J Immunol 1997;158:2090-2098. (Pubitemid 127469990)
40. Gilfillan MC, Noel PJ, Podack ER, Reiner SL, Thompson CB. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998;160:2180-2187. (Pubitemid 28119897)
41. Valent P, Sotlar K, Horny HP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 2011 Jan 24. [Epub ahead of print].
42. Kneile JR, Tan G, Suster S, Wakely PE Jr. Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferen-tiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma. Histopathology 2006;48:855-861. (Pubitemid 43800946)
43. Alzona M, Jack HM, Fisher RI, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol 1994;153:2861-2867. (Pubitemid 24292513)
44. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER. Structure and expression of murine CD30 and its role in cytokine production. J Immunol 1996;156:442-449. (Pubitemid 26028901)
45. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993;177:213-218. (Pubitemid 23008103)
46. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989;19:157-162. (Pubitemid 19069302)
47. Latza U, Foss HD, Durkop H, et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol 1995;146:463-471.
48. Pfreundschuh M, Pohl C, Berenbeck C, et al. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononu-cleosis. Int J Cancer 1990;45:869-874. (Pubitemid 20179639)
49. Fattovich G, Vinante F, Giustina G, et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996;103:105-110. (Pubitemid 26027380)
50. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997;159:1012-1018. (Pubitemid 127484258)
51. Pizzolo G, Vinante F, Morosato L, et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 1994;8:741-745. (Pubitemid 24163414)
52. Pizzolo G, Vinante F, Nadali G, et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997;108:251-253. (Pubitemid 27223461)
53. Rizzardi GP, Barcellini W, Tambussi G, et al. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 1996;10:F45-F50. (Pubitemid 26370657)
54. Caligaris-Cappio F, Bertero MT, Converso M, et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995;13:339-343.
55. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996;80:311-320.
56. Elewaut D, De Keyser F, Cuvelier C, et al. Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1998;33: 743-748. (Pubitemid 28358059)
57. Gerli R, Muscat C, Bistoni O, et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995;102:547-550. (Pubitemid 26013219)
58. Okumura M, Hidaka Y, Kuroda S, Takeoka K, Tada H, Amino N. Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1997;82:1757-1760. (Pubitemid 127495181)
59. Giacomelli R, Cipriani P, Lattanzio R, et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997;108:42-46. (Pubitemid 27140328)
60. Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 1997;15:3355-3362. (Pubitemid 27485855)
61. Pizzolo G, Romagnani S. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma. Haematologica 1995;80:357-366.
62. Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994;12:793-797. (Pubitemid 24110920)
63. Nadali G, Vinante F, Stein H, et al. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol 1995;13:1355-1360.
64. Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998;91:3011-3016. (Pubitemid 28227554)
65. Zanotti R, Trolese A, Ambrosetti A, et al. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 2002;13:1908-1914. (Pubitemid 36040779)
66. Visco C, Nadali G, Vassilakopoulos TP, et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006;77:387-394. (Pubitemid 44483941)
67. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73:1349-1360. (Pubitemid 23201148)
68. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997;17: 1535-1542. (Pubitemid 27097383)
69. Lee SY, Park CG, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996;183: 669-674.
70. Ansieau S, Scheffrahn I, Mosialos G, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 1996;93:14053-14058. (Pubitemid 26424244)
71. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997;272:2042-2045. (Pubitemid 27058475)
72. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3-9. (Pubitemid 127500814)
73. Hsu PL, Hsu SM. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lympho-ma. Lab Invest 2000;80:1111-1119.
74. Sun X, Yamada H, Shibata K, et al. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. J Immunol 2010;185:2222-2230.
75. Sun X, Yamada H, Shibata K, et al. CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J Immunol 2010;185:7671-7680.
76. Blazar BR, Levy RB, Mak TW, et al. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol 2004;173:2933-2941. (Pubitemid 39141997)
77. Muta H, Boise LH, Fang L, Podack ER. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol 2000;165:5105-5111.
78. Harlin H, Podack E, Boothby M, Alegre ML. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mito-gen-activated protein kinase-dependent mechanism. J Immunol 2002;169:2451-2459.
79. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-520.
80. Oshima Y, Puri RK. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist. Cell Immunol 2001;211: 37-42. (Pubitemid 32917756)
81. Tian ZG, Longo DL, Funakoshi S, et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 1995;55:5335-5341.
82. Gruss HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol 1995;25:2083-2089.
83. Gruss HJ, Ulrich D, Dower SK, Herrmann F, Brach MA. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappabeta transcription factor. Blood 1996;87:2443-2449. (Pubitemid 26086888)
84. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000;96:4307-4312.
85. Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004;199: 1041-1052. (Pubitemid 38619901)
86. Kashkar H, Haefs C, Shin H, et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003;198:341-347. (Pubitemid 36987859)
87. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101:681-689. (Pubitemid 36077593)
88. Cerveny CG, Law CL, McCormick RS, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia 2005;19:1648-1655. (Pubitemid 43090411)
89. Boll B, Hansen H, Heuck F, et al. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005;106:1839-1842. (Pubitemid 41208602)
90. Falini B, Flenghi L, Fedeli L, et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol 1992;82:38-45.
91. Tazzari PL, Bolognesi A, de Totero D, et al. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. Br J Haematol 1992;81:203-211.
92. Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992;339:1195-1196.
93. Hombach A, Jung W, Pohl C, et al. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 1993;55:830-836. (Pubitemid 23354902)
94. Hartmann F, Renner C, Jung W, Pfreundschuh M. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. Leuk Lymphoma 1998;31: 385-392. (Pubitemid 29033960)
95. Hartmann F, Renner C, Jung W, et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997;89:2042-2047. (Pubitemid 27132120)
96. Schnell R, Borchmann P, Staak JO, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003;14:729-736. (Pubitemid 36621773)
97. Sundarapandiyan K, Keler T, Behnke D, et al. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells. J Immunol Methods 2001;248:113-123. (Pubitemid 32167029)
98. Borchmann P, Schnell R, Fuss I, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002;100:3101-3107. (Pubitemid 35217055)
99. Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005;23:4669-4678. (Pubitemid 46224069)
100. Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-3742. (Pubitemid 37409395)
101. Heuck F, Ellermann J, Borchmann P, et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplas-tic large cell lymphoma cell lines. J Immunother 2004;27: 347-353. (Pubitemid 39121923)
102. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodg-kin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-2769. (Pubitemid 47123185)
103. Bowen MA, Olsen KJ, Cheng L, Avila D, Podack ER. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J Immunol 1993;151:5896-5906. (Pubitemid 23340335)
104. Oflazoglu E, Stone IJ, Gordon KA, et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 2007;110:4370-4372. (Pubitemid 351377803)
105. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62: 3736-3742. (Pubitemid 34728855)
106. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111:1848-1854. (Pubitemid 351451492)
107. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-179.
108. Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009;15:6217-6224.
109. Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc{gamma}RIIIa-158 V/F polymorphism. Ann Oncol 2010;21:2246-2254.
110. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005;11:843-852. (Pubitemid 40116913)
111. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcM-MAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102: 1458-1465. (Pubitemid 36988057)
112. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-897.
113. Fromm JR, McEarchern JA, Kennedy DA, Anju T, Shustov AR, Gopal AK. Preclinical and clinical binding properties, internalization kinetics, and clinicopathological activity of brentuximab vedotin (SGN-35): a novel antibody drug conjugate for anaplastic large cell lymphoma and classical Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 1789.
114. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10: 7063-7070. (Pubitemid 39383058)
115. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitu-mour activity in Hodgkin lymphoma. Br J Haematol 2008;142:69-73. (Pubitemid 351783148)
116. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
117. Shustov AR, Advani R, Brice P, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lympho-ma. Blood 2010;116(Suppl. 1): Abstract 961.
118. Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 283.